86 -6 (92) 2026 - Kurbonova Z.Ch., Mirzamudova N.A. - ORTIRILGAN YURAK NUQSONLARI BO‘LGAN BEMORLARDA GOMOSISTEIN VA GEMOSTAZ KO‘RSATKICHLARI: TROMBOTIK ASORATLAR RIVOJLANISHIDAGI AHAMIYATI

ORTIRILGAN YURAK NUQSONLARI BO‘LGAN BEMORLARDA GOMOSISTEIN VA GEMOSTAZ KO‘RSATKICHLARI: TROMBOTIK ASORATLAR RIVOJLANISHIDAGI AHAMIYATI

Kurbonova Z.Ch., Mirzamudova N.A. - Toshkent Davlat Tibbiyot Universiteti

Rezyume

Maqsad: Orttirilgan yurak nuqsonlari (OYuN) bo‘lgan bemorlarda qon zardobi gomosistein (HCY) darajasi hamda gemostaz ko‘rsatkichlari o‘rtasidagi bog‘liqlikni va bu o‘zgarishlarning trombotik asoratlar rivojlanishidagi ahamiyatini baholash. Usullar: Tadqiqotga 63 nafar OYuN bilan og‘rigan bemor (27 nafarida mitral-aortal zararlanish, 36 nafarida mitral porok), 30 nafar sog‘lom shaxs (nazorat guruhi) va 30 nafar qiyosiy guruh (O‘YuN bo‘lmagan yurak-qon tomir kasalliklari) kiritildi. Barcha ishtirokchilarda HCY miqdori, protrombin indeksi (PTI), protrombin vaqti (PV), xalqaro me’yorlashtirilgan nisbat (MNO), faollashtirilgan qisman tromboplastin vaqti (APTT), trombin vaqti (TT) hamda fibrinogen konsentratsiyasi o‘rganildi. Statistik tahlil Kruskal-Wallis mezoni bilan amalga oshirildi, p<0,05 ahamiyatli deb qabul qilindi. Natijalar: HCY darajasi bemor guruhlarida nazoratga nisbatan ishonchli yuqori bo‘ldi: mitral-aortal zararlanishda 11,75±6,55 mkmol/L, mitral porokda 9,70±6,33 mkmol/L, nazoratda 7,52±2,56 mkmol/L (H=8,65; p=0,03). PTI bemorlarda sezilarli pasaygan (65,52±27,98% va 73,71±25,49%), nazoratda 91,76±15,31% (H=24,03; p<0,001). PV va MNO ishonchli yuqoriligi (H=10,29; p=0,02 va H=27,23; p<0,001), APTT va TT uzayganligi (H=8,13; p=0,04 va H=8,92; p=0,03) aniqlandi. Fibrinogen bo‘yicha guruhlararo farq topilmadi (p=0,38). Trombotik asoratli bemorlarning dastlabki tahlili HCY yuqoriligi bilan gemostaz siljishi o‘rtasidagi bog‘liqlikni ko‘rsatmoqda. Xulosa: Orttirilgan yurak nuqsonlarida gipergomosisteinemiya gemostazning giperkoagulyatsion siljishi bilan kechadi va bu holat trombotik asoratlar rivojlanishiga zamin yaratishi mumkin.

Kalit so‘zlar: orttirilgan yurak nuqsonlari, gomosistein, gemostaz, giperkoagulyatsiya, trombotik asoratlar.

First page

509

Last page

515

For citation:Kurbonova Z.Ch., Mirzamudova N.A. - ORTIRILGAN YURAK NUQSONLARI BO‘LGAN BEMORLARDA GOMOSISTEIN VA GEMOSTAZ KO‘RSATKICHLARI: TROMBOTIK ASORATLAR RIVOJLANISHIDAGI AHAMIYATI//New Day in Medicine 6(92)2026 509-515 https://newdayworldmedicine.com/en/new_day_medicine/6-92-2026

List of References

1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP III, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227. doi:10.1161/CIR.0000000000000923.
2. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632. doi:10.1093/eurheartj/ehab395.
3. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.
4. Cattaneo M. Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost. 2016;42(2):164-171. doi:10.1055/s-0035-1564846.
5. Undas A. Homocysteine and thrombosis: a 2020 update. Pol Arch Intern Med. 2020;130(10):866-872. doi:10.20452/pamw.15477.
6. Pizzolo F, Salvagno GL, Lippi G. Homocysteine and hemostasis: a bidirectional relationship. Clin Chem Lab Med. 2018;56(10):1655-1661. doi:10.1515/cclm-2018-0187.
7. Shah H, Jan MU, Altaf A, Salahudin M. Correlation of hyper-homocysteinemia with coronary artery disease in absence of conventional risk factors among young adults. J Saudi Heart Assoc. 2018;30(4):305-310. doi:10.1016/j.jsha.2018.04.002.
8. Yao Y, Gao LJ, Zhou Y, Zhao JH, Lv Q, Dong JZ, et al. Effect of advanced age on plasma homocysteine levels and its association with ischemic stroke in non-valvular atrial fibrillation. J Geriatr Cardiol. 2017;14(12):743-749. doi:10.11909/j.issn.1671-5411.2017.12.004.
9. Van der Bom JG, Heckbert SR, Lumley T, Cushman M, Psaty BM, Rosendaal FR, et al. Homocysteine, coagulation factors, and incident venous thrombosis. Blood. 2016;127(12):1622-1629. doi:10.1182/blood-2015-10-674143.
10. ALSolami AA, Almalki AA, Alhedyan SY, Alghamdi A, Alzahrani SM, Dause WR, et al. Plasma Homocysteine Levels and Cardiovascular Events in Patients With End-Stage Renal Disease: A Systematic Review. Cureus. 2023;15(6):e40357. doi:10.7759/cureus.40357.

    file

    download